Back to results
US 2014/0005127 A1Published application
Methods of treating muscular wasting diseases using nf-kb activation inhibitors
AssigneeTheralogics, Inc.
InventorsDenis C. Guttridge, Albert S. Baldwin
Life of this patent
Estimating the term…
Abstract
Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-κB activation inhibitor capable of blocking the activation of NF-κB.
Claims20
A method of treating muscular dystrophy in a subject, the method comprising administering to the subject an NF-κB activation inhibitor or a mimetic thereof comprising:
- (a) a polypeptide having an amino acid sequence of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, or SEQ ID NO:
- 18;
- (b) a polypeptide which comprises a conservative amino acid substitution of the amino acid sequence of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, or SEQ ID NO:
- 18;
- or
- (c) a naturally occurring amino acid sequence variant of the amino acid sequence of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, or SEQ ID NO:
- 18.
52 more elements
Dependencies are inferred from the claim text.